logo
  

Magellan Health Affirms 2014 Outlook, Sees 2015 Earnings Above View

Healthcare management company Magellan Health Inc. (MGLN) on Tuesday affirmed its financial outlook for fiscal 2014. The company also forecast adjusted earnings for fiscal 2015 above analysts' estimates and revenues in line with their expectations.

For fiscal 2014, Scottsdale, Arizona-based Magellan Health affirmed its financial outlook, which it most recently updated in October. At that time, the company forecast full-year adjusted earnings of $3.21 to $3.72 per share on revenues of $3.6 billion to $3.8 billion.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $2.62 per share for the year on revenues of $3.76 billion. Analysts' estimates typically exclude special items.

Looking ahead to fiscal 2015, Magellan Health forecast net income in a range of $1.90 to $2.50 per share, adjusted net income of $3.28 to $3.73 per share, and net revenues of $4.25 billion to $4.49 billion.

Street expects the company to report earnings of $2.67 per share for the year on revenues of $4.47 billion.

The company expects segment profit for the year in a range of $265 million to $285 million and cash flow from operations of $171 million to $195 million.

Jonathan Rubin, CFO of Magellan Health said, "Looking ahead to 2015, We are projecting revenue growth of slightly less than 20 percent, and expect to report revenues of over $4 billion for the first time in the company's history."

Magellan Health said it has completed its previous $300 million share repurchase authorization, and now commenced the new, two-year $200 million program approved by its board of directors in October. Under this new program, through Monday, December 15, the company has repurchased about 117,000 shares for a total cost of $7.2 million.

MGLN closed Monday's trading at $58.54, down $1.49 or 2.48 percent on a volume of 200,526 shares.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Automajor General Motors plans to end production of its gasoline-powered Chevrolet Malibu car later this year as it prepares to produce new electric vehicles, reports said. Chevy Malibu, which was launched in 1964, has since been sold more than 10 million in numbers. The Malibu will end its production in November. Ride-hailing and delivery platform Uber Technologies, Inc. (UBER) reported Wednesday a net loss for the first quarter that sharply widened from last year, hurt by a huge net unrealized loss related to the revaluation of Uber's equity investments. Loss per share for the quarter missed analysts' expectations, while quarterly revenues topped it. Shares of Siemens Energy AG were gaining more than 12 percent in German trading after the company on Wednesday raised its outlook for fiscal 2024 after reporting a profit in its second quarter, compared to last year's loss, amid positive market environment. Meanwhile, second-quarter orders were lower than last year, and the company maintained annual earnings forecast.

This week, we feature J&J’s Talc litigation closure,Emergent’s strategic changes for growth ,Pfizer’s breakthrough hemophilia B gene therapy approval,Novartis’s strategic Mariana Oncology Buyout, and Beyfortus Breakthrough RSV prevention.

View More Videos
Follow RTT